SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

The primary catalyst for movement is the cancellation of Larry Ellison's plan to sell up to 50 million shares, which the community views as a bullish removal of a major supply overhang. Traders are heavily debating whether this news will trigger a short squeeze or if lingering concerns regarding the company's high capital expenditures and debt load will pressure the stock.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The community is discussing the rapid and significant collapse of the meme coin shortly after its launch, with many traders labeling the event a market rug pull. Investors express frustration over substantial financial losses, while the conversation remains heavily polarized by political sentiment and widespread skepticism toward the project.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid highly polarized sentiment, with some traders debating potential price floors and technical setups while vocal critics mock long-term holders as "suckers" for the asset's sustained multi-year downtrend. Discussion frequently centers on frustration over previous missed profit opportunities and skepticism regarding the project's long-term utility.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BNTX is trending following significant volatility surrounding its latest quarterly results, where it reported wider net losses and lowered revenue guidance. Community sentiment is mixed, with some traders expressing concern over the departure of the company's co-founders and uncertainty regarding its oncology pipeline, while others argue the stock remains undervalued due to its substantial cash reserves and extensive Phase 3 trial portfolio.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing active discussion focused on community-led efforts to increase engagement and speculation regarding potential long-term price appreciation, despite frequent complaints about stagnant performance. Traders are actively debating the viability of holding meme coins versus rotating into other assets amid a broader, mixed sentiment regarding the crypto market's momentum.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending following a fiscal fourth-quarter earnings report that beat analyst expectations for both revenue and EPS, while providing forward guidance that exceeded consensus estimates. The strong results, driven by robust cloud data center demand and mass-capacity storage growth, triggered an after-hours rally and alleviated some market concerns regarding the durability of the AI-driven storage cycle.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant stock volatility driven by heavy insider selling, concerns over lock-up period expirations, and investor reactions to the company's competitive position against major GPU providers. While some traders view the recent price decline as a buying opportunity based on the company's wafer-scale technology and infrastructure growth, others remain skeptical, citing valuation concerns and aggressive short-selling activity.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

Vechain is currently trending amid widespread community frustration regarding its long-term price performance and ongoing decline in market rank. Traders are debating whether the asset is a viable long-term investment or a failed project, with sentiment polarized between those continuing to accumulate at lower levels and others exiting their positions.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is facing downward pressure amid concerns over North American snack sales and broader consumer spending constraints, leading to debate among traders regarding its long-term growth potential and dividend sustainability. Despite the weakness, some investors view the stock as an undervalued defensive play due to its historical dividend reliability and international revenue strength.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics is receiving attention following positive clinical trial data, including successful results from the Phase 1/2 trial for its gene therapy candidate OPGx-BEST1 and FDA alignment on Phase 3 trial design. While many traders express bullish sentiment based on the clinical progress and analyst price target upgrades, some participants remain concerned about the company's capital management, including ongoing ATM usage and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IceCure Secures China NMPA Approval for ProSense Cryoablation System

ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.

IceCure Medical Receives Regulatory Approval to Market ProSense in China

IceCure Medical Receives Regulatory Approval to Market ProSense in China IceCure Medical Receives Regulatory Approval to Market ProSense in China PR Newswire CAESAREA, Israel, Sept. 10, 2026 CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ --IceCure Medical Ltd.(NASDAQ: ICCM) ("IceCure," "IceCure...

IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands

IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands PR Newswire CAESAREA, Israel, Aug. 24, 2026 Agreement expands ProSense commercialization in the...

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation PR Newswire CAESAREA, Israel, Aug. 20, 2026 Patients are expected to enroll in the...

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation PR Newswire CAESAREA, Israel, Aug. 13, 2026 New review by...

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical Ltd Q2 2026 Earnings Call Summary...

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year PR Newswire CAESAREA, Israel, Aug. 12, 2026 The Company is advancing commercial execution...

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates

Establishment Labs (ESTA) delivered earnings and revenue surprises of -14.71% and +3.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment PR...

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Icecure Medical Ltd

ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

Equity

Bullish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ICCM Icecure Medical Ltd

Fundamentals

Latest ICCM News